{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:59:01Z","timestamp":1790787541972,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Nhwa Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00931-1","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T03:13:41Z","timestamp":1747278821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A study on the pharmacokinetic bioequivalence of oral tablet formulations of riluzole among healthy volunteers utilizing HPLC-MS\/MS"],"prefix":"10.1186","volume":"26","author":[{"given":"Fei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BoYang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanggang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"0","key":"931_CR1","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/j.neuint.2024.105876","volume":"180","author":"S Ramaish","year":"2024","unstructured":"Ramaish S, Sidharth M, Zuber K, Ghanshyam D Gupta, Acharan S Narula. Therapeutic potential of oleanolic acid in modulation of PI3K\/Akt\/mTOR\/STAT-3\/GSK-3\u03b2 signaling pathways and neuroprotection against methylmercury-induced neurodegeneration. Neurochem Int. 2024;180(0):0. https:\/\/doi.org\/10.1016\/j.neuint.2024.105876.","journal-title":"Neurochem Int"},{"issue":"1","key":"931_CR2","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1515\/hmbci-2024-0007","volume":"46","author":"K Zeinab","year":"2024","unstructured":"Zeinab K, Iman A, Majid G. Association between cerebrospinal fluid chitotriosidase level and amyotrophic lateral sclerosis: a systematic review. Horm Mol Biol Clin Investig. 2024;46(1):0. https:\/\/doi.org\/10.1515\/hmbci-2024-0007.","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"0","key":"931_CR3","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1080\/21678421.2024.2375330","volume":"26","author":"C Philippe","year":"2024","unstructured":"Philippe C, Nathalie G, Pierre-Fran\u00e7ois P, Marie-Helene S, Annie V, Philippe C. Treatment continuity of amyotrophic lateral sclerosis with available riluzole formulations: state of the art and current challenges in a \u2018real-world\u2019 setting. Amyotroph Lateral Scler Frontotemporal Degener. 2024;26(0):0. https:\/\/doi.org\/10.1080\/21678421.2024.2375330.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"931_CR4","doi-asserted-by":"publisher","unstructured":"Rosario V, Filippo DM, Salvatore T, Antonio C, Umberto M, Maurizio G, Francesca P, Sara C, Enrico M, Francesca DP, Grazia Z, Giorgio P, Emilio M, Daniela P, Barbara I, Stefano C, Giuseppe F, Paolina S, Fabiola. De Marchi., Letizia, Mazzini., Cristina, Moglia., Andrea, Calvo., Adriano, Chi\u00f2. Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995\u20132018): Results From the Piemonte and Valle d\u2019Aosta Registry. Neurology. 2025;104(8):0. https:\/\/doi.org\/10.1212\/WNL.0000000000213467","DOI":"10.1212\/WNL.0000000000213467"},{"issue":"9","key":"931_CR5","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1002\/j.1552-4604.1997.tb05630.x","volume":"37","author":"A Le Liboux","year":"1998","unstructured":"Le Liboux A, Lefebvre. P, Le Roux Y, Truffinet. P, Aubeneau. M, Kirkesseli S, Montay G. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J Clin Pharmacol. 1998;37(9):0. https:\/\/doi.org\/10.1002\/j.1552-4604.1997.tb05630.x.","journal-title":"J Clin Pharmacol"},{"issue":"0","key":"931_CR6","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/s0022-510x(01)00613-x","volume":"191","author":"GJ Groeneveld","year":"2001","unstructured":"Groeneveld GJ, van Kan HJ, Tora\u00f1o. JS, Veldink JH, Guchelaar HJ, Wokke JH, den Berg. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS. J Neurol Sci. 2001;191(0):0. https:\/\/doi.org\/10.1016\/s0022-510x(01)00613-x. van.","journal-title":"J Neurol Sci"},{"issue":"11","key":"931_CR7","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1007\/s40262-018-0655-4","volume":"57","author":"D Ranjeet Prasad","year":"2018","unstructured":"Ranjeet Prasad D, Jayachandra R, Nuggehally B, Srinivas R. Two decades-long journey from riluzole to Edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics. Clin Pharmacokinet. 2018;57(11):0. https:\/\/doi.org\/10.1007\/s40262-018-0655-4.","journal-title":"Clin Pharmacokinet"},{"issue":"0","key":"931_CR8","doi-asserted-by":"publisher","first-page":"0","DOI":"10.2147\/DDDT.S123776","volume":"11","author":"D Ann Margaret","year":"2017","unstructured":"Ann Margaret D, Alan S. Riluzole 5\u00a0mg\/ml oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. Drug Des Devel Ther. 2017;11(0):0. https:\/\/doi.org\/10.2147\/DDDT.S123776.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"931_CR9","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1093\/toxsci\/kfaa019","volume":"175","author":"M Diane","year":"2020","unstructured":"Diane M, Longo., Lisl KM, Shoda., Brett A, Howell., Vladimir C, Robert M, Berman., Irfan A, Qureshi. Assessing effects of BHV-0223 40\u00a0mg Zydis Sublingual formulation and riluzole 50\u00a0mg oral tablet on liver function test parameters utilizing DILIsym. Toxicol Sci. 2020;175(2):0. https:\/\/doi.org\/10.1093\/toxsci\/kfaa019.","journal-title":"Toxicol Sci"},{"issue":"12","key":"931_CR10","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/j.clinthera.2019.09.016","volume":"41","author":"B Benjamin Rix","year":"2019","unstructured":"Benjamin Rix B, Paolo B, Sara C. Riluzole oral suspension: bioavailability following percutaneous gastrostomy Tube-modeled administration versus direct oral administration. Clin Ther. 2019;41(12):0. https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.016.","journal-title":"Clin Ther"},{"issue":"1","key":"931_CR11","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1002\/cpdd.1168","volume":"12","author":"W James","year":"2022","unstructured":"James W, Stephen A, Antoinette H, Alan B, Hill. Pharmacokinetics, bioavailability, and swallowing safety with riluzole oral film. Clin Pharmacol Drug Dev. 2022;12(1):0. https:\/\/doi.org\/10.1002\/cpdd.1168.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"931_CR12","doi-asserted-by":"crossref","unstructured":"Irfan Q, et al. A Pharmacokinetic bioequivalence study comparing Sublingual riluzole (BHV-0223) and oral tablet formulation of riluzole in healthy volunteers. Clin Pharmacol Drug Dev. 2019;9(4).","DOI":"10.1002\/cpdd.747"},{"issue":"9013","key":"931_CR13","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/s0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L, Bensimon. G, Leigh PN, Guillet. P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis\/riluzole study group II. Lancet. 1996;347(9013):0. https:\/\/doi.org\/10.1016\/s0140-6736(96)91680-3.","journal-title":"Lancet"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00931-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T03:13:42Z","timestamp":1747278822000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00931-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00931-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5696871\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial received ethical approval from the Ethics Committee of Zhejiang Hospital, bearing the approval number 2023 Clinical Review (02G). The study was independently conducted at the Phase I Clinical Trial Research Center of Zhejiang Hospital, spanning from April 13, 2023, to May 23, 2023. The research adhered strictly to the standards set by the Declaration of Helsinki, the Guidelines of Good Clinical Practice, and all other pertinent guiding principles. All participants involved in the trial provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}